Advertisement
Singapore markets open in 2 hours 51 minutes
  • Straits Times Index

    3,293.13
    +20.41 (+0.62%)
     
  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     
  • Dow

    38,460.92
    -42.77 (-0.11%)
     
  • Nasdaq

    15,712.75
    +16.11 (+0.10%)
     
  • Bitcoin USD

    64,301.33
    -2,102.73 (-3.17%)
     
  • CMC Crypto 200

    1,385.35
    -38.75 (-2.72%)
     
  • FTSE 100

    8,040.38
    -4.43 (-0.06%)
     
  • Gold

    2,328.90
    -9.50 (-0.41%)
     
  • Crude Oil

    82.84
    +0.03 (+0.04%)
     
  • 10-Yr Bond

    4.6520
    +0.0540 (+1.17%)
     
  • Nikkei

    38,460.08
    +907.92 (+2.42%)
     
  • Hang Seng

    17,201.27
    +372.34 (+2.21%)
     
  • FTSE Bursa Malaysia

    1,571.48
    +9.84 (+0.63%)
     
  • Jakarta Composite Index

    7,174.53
    -7,110.81 (-49.78%)
     
  • PSE Index

    6,572.75
    +65.95 (+1.01%)
     

Insights into UniQure’s Financial Performance

Insights into UniQure’s Financial Performance

The major sources of UniQure’s (QURE) revenues are from licensing revenue and collaboration revenue. In fiscal 2017, its license revenue from related parties was $4.1 million compared with $3.9 million in fiscal 2016. A major part of UniQure’s collaboration revenues comes from its collaboration agreement with Bristol-Myers Squibb (BMY) entered into in 2015.